BACKGROUND In recent reports, re-irradiation with stereotactic body radiotherapy for lung tumors in patients previously treated with thoracic radiation therapy resulted in several serious toxicities. Serious non-lung toxicities were observed mostly in patients with central tumors, but we experienced a case of fatal gastric perforation after a second stereotactic body radiotherapy in a patient w...

Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the...

background: stereotactic body radiotherapy (sbrt) has emerged as an effective treatment for localized prostate cancer. however, prostate-specific antigen (psa) kinetics after sbrt has not been well characterized. the objective of the current study is to analyze the rate of psa decline and psa nadir following hypofractonated sbrt in localized prostate cancer. materials and methods: from 2008 to ...

The aim of this study was to describe our initial experience with a gold flexible linear fiducial marker and to evaluate the safety and technical and clinical efficacy of stereotactic body radiotherapy using this marker for malignant liver tumors. Between July 2012 and February 2015, 18 patients underwent percutaneous fiducial marker placement before stereotactic body radiotherapy for malignant...

The following Protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered s...

©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 46 Applies to all products admin...

When Policy Topic is covered Stereotactic radiosurgery using a gamma or LINAC unit may be considered medically necessary for the following indications:  arteriovenous malformations;  acoustic neuromas;  pituitary adenomas;  non-resectable, residual, or recurrent meningiomas;  craniopharyngiomas;  glomus jugulare tumors;  solitary or multiple brain metastases in patients having good perfo...

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered s...

Patient Selection Criteria Coverage for the use of stereotactic radiosurgery (SRS) using a gamma or linear-accelerator (LINAC) will be considered when any of the following criteria are met:  Arteriovenous malformations;  Acoustic neuromas;  Pituitary adenomas;  Non-resectable, residual or recurrent meningiomas;  Craniopharyngiomas;  Glomus jugulare tumors;  Solitary or multiple brain met...